{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Schizophrenia+Spectrum+and+Other+Psychotic+Disorders&page=43",
    "query": {
      "condition": "Schizophrenia Spectrum and Other Psychotic Disorders",
      "page": 43
    },
    "page_size": 10
  },
  "pagination": {
    "page": 43,
    "page_size": 10,
    "total_count": 1652,
    "total_pages": 166,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Schizophrenia+Spectrum+and+Other+Psychotic+Disorders&page=44&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Schizophrenia+Spectrum+and+Other+Psychotic+Disorders&page=42&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T15:40:26.261Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02921243",
      "title": "Schizophrenia and the Gut Microbiome",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 11,
      "start_date": "2016-10-01",
      "completion_date": "2019-06-18",
      "has_results": false,
      "last_update_posted_date": "2019-08-19",
      "last_synced_at": "2026-10-18T15:40:26.261Z",
      "location_count": 1,
      "location_summary": "Catonsville, Maryland",
      "locations": [
        {
          "city": "Catonsville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02921243"
    },
    {
      "nct_id": "NCT00742079",
      "title": "Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "D-cycloserine",
          "type": "DRUG"
        },
        {
          "name": "Cognitive Behavioral Therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 21,
      "start_date": "2006-09",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2017-12-19",
      "last_synced_at": "2026-10-18T15:40:26.261Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00742079"
    },
    {
      "nct_id": "NCT05628103",
      "title": "A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "SEP-363856",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 101,
      "start_date": "2022-12-19",
      "completion_date": "2024-04-01",
      "has_results": true,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-10-18T15:40:26.261Z",
      "location_count": 25,
      "location_summary": "Anaheim, California • Bellflower, California • Culver City, California + 19 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Lemon Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05628103"
    },
    {
      "nct_id": "NCT01122927",
      "title": "Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Adolescent Schizophrenia",
        "Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features"
      ],
      "interventions": [
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 524,
      "start_date": "2010-07",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2016-02-08",
      "last_synced_at": "2026-10-18T15:40:26.261Z",
      "location_count": 23,
      "location_summary": "Dothan, Alabama • Downey, California • Miami, Florida + 19 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01122927"
    },
    {
      "nct_id": "NCT05660018",
      "title": "TMS Related Biomarker Assessments",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia Schizoaffective",
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "active rTMS first, then sham rTMS",
          "type": "DEVICE"
        },
        {
          "name": "sham rTMS first, then active rTMS",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2023-01-07",
      "completion_date": "2025-02-14",
      "has_results": true,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-10-18T15:40:26.261Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05660018"
    },
    {
      "nct_id": "NCT01884025",
      "title": "Get Moving and Get Well - Pilot Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Bipolar Disorder",
        "Major Depression",
        "Post Traumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "Get Moving and Get Well",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Health and Humor Class",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 27,
      "start_date": "2013-06",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2018-11-05",
      "last_synced_at": "2026-10-18T15:40:26.261Z",
      "location_count": 1,
      "location_summary": "North Little Rock, Arkansas",
      "locations": [
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01884025"
    },
    {
      "nct_id": "NCT02796859",
      "title": "Siltuximab in Schizophrenia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia",
        "Psychotic Disorders"
      ],
      "interventions": [
        {
          "name": "Siltuximab",
          "type": "DRUG"
        },
        {
          "name": "normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brian Miller",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2016-05",
      "completion_date": "2023-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-07-21",
      "last_synced_at": "2026-10-18T15:40:26.261Z",
      "location_count": 1,
      "location_summary": "Augusta, Georgia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02796859"
    },
    {
      "nct_id": "NCT05658510",
      "title": "Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Agitation,Psychomotor",
        "Bipolar I Disorder",
        "Bipolar II Disorder",
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Schizophreniform Disorders"
      ],
      "interventions": [
        {
          "name": "BXCL501",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioXcel Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 452,
      "start_date": "2022-11-21",
      "completion_date": "2025-08-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-10-18T15:40:26.261Z",
      "location_count": 24,
      "location_summary": "Bellflower, California • Cerritos, California • Culver City, California + 19 more",
      "locations": [
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Lemon Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05658510"
    },
    {
      "nct_id": "NCT02686697",
      "title": "Carnosine and Cognitive Training in Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "L-Carnosine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Cognitive Training",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Abraham Reichenberg",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 60,
      "start_date": "2015-12-01",
      "completion_date": "2022-07-19",
      "has_results": false,
      "last_update_posted_date": "2022-08-23",
      "last_synced_at": "2026-10-18T15:40:26.261Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02686697"
    },
    {
      "nct_id": "NCT02212613",
      "title": "Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder and Irritability"
      ],
      "interventions": [
        {
          "name": "Brexpiprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 0,
      "start_date": "2014-09",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2016-07-07",
      "last_synced_at": "2026-10-18T15:40:26.261Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02212613"
    }
  ]
}